Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...

Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...

As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

A home blood pressure telemonitoring (HBPT) program effectively reduced BP in real-world clinical settings, but its enrollment expenses increased overall costs. The HBPT program reduced BP clinic ...

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized ...

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII ...

A successful collaboration involving a trio of research institutions has yielded a roadmap toward an economically viable process for using enzymes to recycle plastics. The researchers, from the ...